This protocol addresses a molecularly defined subset of non-small cell lung cancer (NSCLC): cases that are advanced or metastatic and harbour a RET gene fusion. Identifying this alteration is clinically significant because it defines both prognosis and therapeutic direction.
RET gene fusions occur in approximately 1–2% of patients with NSCLC and are more commonly identified in adenocarcinoma histology. The presence of a RET gene fusion is associated with responsiveness to oral RET-targeted kinase inhibitors regardless of which fusion partner is involved. Molecular testing to confirm RET fusion status is therefore a key step before treatment selection in this population.
For patients whose disease progresses, the protocol includes subsequent systemic therapy options — among them a targeted oral agent with activity against RET-driven tumours. The full regimen, sequencing, and decision criteria are detailed in the structured protocol.